Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says

 
• By Sue Sutter
  
Sun and clouds
The gastric cancer treatment landscape has brightened, putting a cloud over Keytruda’s accelerated approval for third-line use. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers